PMID- 2167146
OWN - NLM
STAT- MEDLINE
DCOM- 19900926
LR  - 20220409
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 66
IP  - 5
DP  - 1990 Sep 1
TI  - Better survival after combined modality care for adults with Wilms' tumor. A 
      report from the National Wilms' Tumor Study.
PG  - 827-30
AB  - Adults with Wilms' tumor (WT) have had a poor prognosis. More recently, therapies 
      used in children, who have a better outlook, are also being employed for adults. 
      This study was undertaken to see whether adults with WT have benefited. The 
      results of treatment of 27 adults with WT were reported to the National Wilms' 
      Tumor Study (NWTS) from 1979 to 1987. The ages of the 27 adults ranged from 16 to 
      74 years (median, 24 years). Four had anaplastic WT, and 23 had favorable 
      histology (FH) WT. All but one patient underwent nephrectomy, 21 were given 
      postoperative radiation therapy, and 25 received chemotherapy. The agents used 
      most often included actinomycin D (AMD), vincristine (VCR), and doxorubicin 
      (Adriamycin; ADR). There were six Stage I, five Stage II, four Stage III, 11 
      Stage IV, and one Stage V patients. The 3-year survival rate is 67%. These 
      results are better than the 24% reported by the NWTS in the past for adults with 
      WT. Analyses of the therapies given to the 27 adults lead to the following 
      recommendations: for Stage I/FH patients, 6 months of postoperative chemotherapy 
      using AMD + VCR without postoperative radiation therapy; and for Stage II, III, 
      and IV/FH, VCR + AMD + ADR for 15 months + 2000 cGy to the tumor bed, 1200 to 
      1500 cGy to the lungs, 2000 cGy to the liver, and 3000 cGy to other sites as 
      appropriate in patients with metastases at diagnosis.
FAU - Arrigo, S
AU  - Arrigo S
AD  - Department of Radiation Oncology, Hospital of the University of Pennsylvania, 
      Philadelphia 19104.
FAU - Beckwith, J B
AU  - Beckwith JB
FAU - Sharples, K
AU  - Sharples K
FAU - D'Angio, G
AU  - D'Angio G
FAU - Haase, G
AU  - Haase G
LA  - eng
GR  - CA-42326/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 1CC1JFE158 (Dactinomycin)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Combined Modality Therapy
MH  - Dactinomycin/administration & dosage
MH  - Doxorubicin/administration & dosage
MH  - Humans
MH  - Kidney Neoplasms/drug therapy/*mortality/radiotherapy
MH  - Middle Aged
MH  - Radiotherapy Dosage
MH  - Vincristine/administration & dosage
MH  - Wilms Tumor/drug therapy/*mortality/radiotherapy
EDAT- 1990/09/01 00:00
MHDA- 1990/09/01 00:01
CRDT- 1990/09/01 00:00
PHST- 1990/09/01 00:00 [pubmed]
PHST- 1990/09/01 00:01 [medline]
PHST- 1990/09/01 00:00 [entrez]
AID - 10.1002/1097-0142(19900901)66:5<827::aid-cncr2820660502>3.0.co;2-0 [doi]
PST - ppublish
SO  - Cancer. 1990 Sep 1;66(5):827-30. doi: 
      10.1002/1097-0142(19900901)66:5<827::aid-cncr2820660502>3.0.co;2-0.